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Background & aims: To investigate the effects of two different glucose infusions on glucose homeostasis
and amino acid metabolism in post-surgical children.
Methods: This randomized crossover study evaluated glucose and amino acidmetabolism in eight children
(age 9.8 1.9months, weight 9.5 1.1 kg) admitted to a pediatric intensive care unit in a tertiary university
hospital after surgical correction for non-syndromal craniosynostosis. Patientswere randomized to receive
low (LG; 2.5 mg kg1 min1) and standard (SG; 5.0 mg kg1 min1) glucose infusion in a crossover setting.
After a bolus (4 g kg1) of deuterium oxide, we conducted a primed, constant, 8 h tracer infusion with
[6,6-2H2]Glucose, [1-13C]Leucine, [ring-2H5]Phenylalanine and [3,3-2H2]Tyrosine.
Results: SG resulted in hyperglycemia (deﬁned as > 6.1 mmol L1), while during LG plasma glucose levels
were normoglycemic (5.9  0.6 vs. 7.5  1.7 mmol L1; LG vs. SG respectively, p ¼ 0.02). Hypoglycemia did
not occur during LG infusion. Endogenous glucose production was not fully suppressed during the hyper-
glycemic state under SG and increasedwith reduced glucose infusion (2.6 1.5 vs.1.1 1.4mg kg1 min1;
LG vs. SG; p ¼ 0.05). Whole body protein balance derived from leucine and phenylalanine kinetics was
slightly negative but not further affected with a decrease in glucose infusion.
Conclusions: The current recommended glucose infusion induces hyperglycemia in post-surgical chil-
dren. A reduced glucose infusion safely reduced high glucose levels, while children were capable to
sustain normoglycemia with increased endogenous glucose production. The reduced glucose infusion did
not exacerbate the mild catabolic state in which the patients were.
 2011 Els evier B.V . and NIPR. Open access under the Elsevier OA license.1. Introduction
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nder the Elsevier OA license.glucose oxidation or storage as glycogen and triglycerides on the
other. Critically ill children are at increased risk to a disturbance in
this balance leading to hyper- as well as hypoglycemia.1
Hyperglycemia is a frequent complication and associated with
increased morbidity and mortality in pediatric intensive care units
(PICU’s).2 Notwithstanding the widespread implementation of tight
glucose regimens,3 concerns regarding hypoglycemia have been
raised.4 Recently, insulin therapy to achieve normoglycemia has been
shown to improve morbidity as well as mortality in critically ill
children, but also led tohypoglycemia (40mgdL1e2.2mmolL1)
and severe hypoglycemia (31mg dL1e1.7mmol L1) in 87 (25%)
and 17 (5%) children, respectively.5
The child’s developing brain is more susceptible to hypogly-
cemia which can result in permanent damage.6e8 Furthermore,
young age is a risk factor for developing hypoglycemia, especially
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risks of insulin therapy in the pediatric population.11,12
An alternative to insulin therapy is to reduce the amount of
glucose infusion in post-surgical children admitted to the PICU. This
approach, however, also has two potential detrimental side-effects;
an increased risk for hypoglycemia and an ampliﬁcation of an
already increased protein catabolism. Currently no data exist on the
impact of different glucose infusions on glucose kinetics and amino
acid metabolism in post-surgical children admitted to the PICU.
We hypothesized that in post-surgical children, reduced glucose
infusion will improve plasma glucose levels without affecting
glucose production rates or amino acid metabolism. Therefore, our
ﬁrst objective was to determine the impact of standard or low
glucose infusions on glucose homeostasis and kinetics. Our second
objective was to determine whether a low glucose infusion would
affect protein and amino acid catabolism.
2. Methods
2.1. Patient characteristics
The study protocol was approved by the Medical Ethical
Committee of the Erasmus Medical Center, Rotterdam, the
Netherlands. The studies were performed in children after surgical
correction for non-syndromal craniosynostosis within 6 h after
admission to the PICU of the Erasmus Medical Center - Sophia
Children’s Hospital. Written informed consent was obtained from
the parents. All were assessed by the Pediatric Logistic Organ
Dysfunction (PELOD) score,13 Pediatric Index of Mortality
(PIM2)14,15 and the Pediatric Risk of Mortality III (PRISM III) score,16
which are validated measures of the severity of multiple organ
dysfunction in PICU’s. Patients with metabolic diseases, diabetes
mellitus, primary liver, or renal failure were excluded.
2.2. Study design
The experimental design, shown in Fig. 1, consisted of a cross-
over design, with a 4 h period of intravenous low glucose infusion
(LG; 2.5 mg kg1 min1) versus a 4 h period of standard glucose
infusion (SG; 5.0 mg kg1 min1).17 Patients were randomized for
the order of glucose infusion through a computer generated
envelop. Laboratory personnel, nursing staff and investigators were
blinded until analyses were ﬁnished. Six hours after admission
(t ¼ 0) to the PICU, an intravenous deuterium oxide infusion (2H2O;
4 gr kg1) was administered in 1 h to prime the body water pool.
Two hours later (t ¼ 120), after obtaining baseline blood samples,
the intravenous glucose infusion as per standard care
(4.0e6.0 mg kg1 min1)17 was stopped and the study glucose
infusion (SG or LG) started. Simultaneously, patients received
a primed, continuous, 8 h intravenous tracer infusion (see below).
Four hours after start of the tracer infusion (t ¼ 360) the glucose
infusion was switched.Fig. 1. Schematic presentation of the tracer infusion study in eight post-surgical infants rece
infusion. Black triangles indicate time points for plasma collection for laboratory parame
production (VCO2) measurements.2.3. Tracer infusion studies
All isotope tracers (Cambridge Isotope Laboratories, Andover,
MA, USA) were tested for sterility and pyrogenicity after they were
compounded at the investigational pharmacy at Erasmus Medical
Center, Rotterdam, the Netherlands.
At t ¼ 120, the bicarbonate pool was primed with 2.1 mmol kg1
NaH13CO2, followed by a 8-h primed, continuous tracer infusion
of [6,6-2H2]glucose (40 mmol kg1; 48 mmol kg1 h1), L-[1-13C]
leucine (8 mmol kg1; 8 mmol kg1 h1), [ring-2H5]Phenylalanine
(5.4 mmol kg1; 4.1 mmol kg1 h1), [3,3-2H2]Tyrosine (3.6 mmol kg1;
3.0 mmol kg1 h1). The [ring-2H5]Phenylalanine derived tyrosine
pool was primed with [ring-2H4]Tyrosine (2.5 mmol kg1).
2.4. Measurements and sample analysis
Blood samples were obtained at standard frequent intervals
(Fig. 1), centrifuged (2 min 6000 rpg) and frozen at 80 C until
samples were analyzed.
Isotopic enrichment of deuterium in plasma body water was
determined by isotope ratio mass spectrometry (Delta þ XP IRMS
Thermo Fisher, Bremen, Germany). Enrichments of glucose labeled
with 2H were measured by gas chromatography-mass spectrom-
etry (GCeMS) (GC 6890, MS 5973N; Agilent Technologies, Wil-
mington, DE) using the penta-acetate derivative as previously
described.18,19
Leucine kinetics were calculated from plasma alpha-
ketoisocaproate (a-KIC) enrichment, which were determined by
GCeMS after derivatization to butyldimethyl-silylquinoxalinol
derivatives.20 Plasma isotopic enrichments of [ring-2H5]Phenylala-
nine, [ring-2H4]Tyrosine and [3,3-2H2]Tyrosinewere determined by
GCeMS after using the N-ethoxycarbonylethylester derivative
according to a modiﬁed method of Husek.21
Carbon dioxide production (VCO2), oxygen (VO2) consumption
and respiratory quotient (RQ), were obtained with a metabolic
monitor in canopy mode (Deltatrac I MBM-200, Datex Division
Instrumentarium Corp., Finland). To determine the enrichment of
13CO2 in whole blood, 1.5 mL of perchloric acid 10% was added to
1.5 mL of whole blood in a vacutainer to release the CO2. The
released gas was transferred to a vacuum impermeable glass tube
and 13CO2 was determined with IRMS.22,23
Plasma samples for glucose, insulin, cortisol, triglycerides, and
free fatty acids were determined by standard in-house protocols.
Plasma glucose levels >6.1 mmol L1(>110 mg dL1) were
considered hyperglycemic.24
2.5. Calculations
Whole body kinetics of protein were calculated by conventional
isotope dilution equations using a stochastic model during steady
state enrichment25 and glucose kinetics were estimated using the
Steele equation,26 based upon the last 40min of both study periods.iving either low (LG, 2.5 mg kg1 min1) or standard (SG, 5.0 mg kg1 min1) glucose
ters and isotopic enrichment measurements. Square boxes represent carbon dioxide
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disappearance (Rd) as follows:
Ra ¼ Rd ¼ i

Einf=Epl  1

(1)
where i is the infusion rate of the labeled tracer, Einf is the tracer
enrichment of the infusate and Epl the tracer enrichment in plasma.
2.6. Glucose kinetics
Endogenous glucose production (EGP) rate is calculated as
follows:
EGP ¼ RaGlucose  GIR (2)
where GIR is the total glucose infusion rate in mg kg1 min1.
Fractional gluconeogenesis is calculated as previously
described.19 Brieﬂy, the average enrichment of 2H on each glucose
carbon was calculated with the following equation:
Average ðMþ 1Þd ¼ ðMþ 1Þdðm=z169Þ=6 (3)
where (M þ 1)d(m/z169) is the M þ 1 enrichment of deuterium of
glucose measured using m/z 170/169 and “6” is the number of 2H
labeling sites on the m/z 169 fragment of glucose.
Because body water is the precursor pool for deuterium or
hydrogen, the extent of deuterium labeling of glucose during the
gluconeogenic process when 2H2O is infused is a measure of frac-
tional gluconeogenesis. Therefore, with the average deuterium
enrichment in m/z 170/169 for calculating fractional gluconeogen-
esis (FracGNG), the equation is
FracGNG ¼ average ðMþ 1Þd=EH2O (4)
where EH2O is the deuterium enrichment in body water.
The absolute rate of appearance of plasma glucose from gluco-
neogenesis (RaGNG) and glycogenolysis were calculated as follows:
Gluconeogenesis ¼ RaGluc  FracGNG (5)
Glycogenolysis ¼ EGP Gluconeogenesis (6)
2.7. Amino acid metabolism
Whole body leucine, phenylalanine and tyrosine ﬂuxes were
calculated according to (1) as previously described.27e29
Leucine oxidation rates were calculated as follows;
LeucineOx ¼ VCO2 

E13CO2=69:18
.
½13Ca KIC (7)
where 69.18 is the 13CO2 refraction correction factor for critically ill
children.30 VCO2 is measured in mL/min and converted to mMol/h
by multiplying by 60 min and dividing by 22.4; the number of 1 in
1 mol of an ideal gas at standard temperature and pressure to
convert to mL/min. Non-oxidative leucine disposal (NOLD; leucine
converted into protein synthesis) was calculated as follows:
NOLD ¼ Raleu  LeucineOx (8)
Phenylalanine hydroxylation (rate of phenylalanine conversion
to tyrosine) was calculated as follows;31,32
Hydroxylation ¼Ratyr 

E½2H4tyr=E½2H5Phe



Raphe=iphe þ Raphe

 2:2 ð9Þ
where Raphe and Ratyr are the phenylalanine and tyrosine ﬂuxes;
E[2H4]tyr and E[2H5]Phe are the plasma enrichments; and iphe is theinfusion rate of labeled phenylalanine and the term (Raphe/
(iphe þ Raphe) corrects for the contribution of the tracer infusion to
Raphe. The factor 2.2 is to correct for the secondary deuterium-
isotope kinetic effect for in vivo hydroxylation in fasted state as
described and validated previously.31,32 Non-hydroxylation
phenylalanine disposal (NHPD; phenylalanine converted into
protein synthesis) was calculated as follows:
NHPD ¼ Raphe  Hydroxylation (10)2.8. Whole body protein metabolism
Under the assumption that 1 g of protein contains approxi-
mately 621 mmol of leucine33 and 280 mmol of phenylalanine,34 it is
then possible to convert leucine and phenylalanine kinetics
(mmol kg1 h1) into protein kinetics (g kg1 d1). Whole body
protein turnover was calculated from the model described by
Golden and Waterlow.352.9. Statistical analysis
A prospective power analysis revealed that 8 patients with
complete data, would detect a difference of 20% of plasma glucose
levels (80% power, type I error of 5%). The ShapiroeWilk normality
test was used to determine whether data were normally distrib-
uted. Comparison between the two different glucose infusions at
both infusion rates were made using the paired student’s t-test. For
non-parametric data the Wilcoxon matched pairs test was used.
Data are presented as the mean  standard deviation unless
non-parametric in which case they are presented as median and
interquartile range. Statistical signiﬁcance was considered at
p < 0.05. Repeated measures ANOVA were used to analyze the
effect of glucose infusion on parameters of glucose and protein
metabolism over time and between LG and SG. Data were analyzed
with Graphpad Prism 5.0.3 (Graphpad Software, La Jolla, CA., USA).
This trial was registered in the Dutch trial register (www.
trialregister.nl) under number NTR2079.3. Results
3.1. Patient characteristics
Eight children (9.8  1.9 months) admitted to the PICU after
surgical correction for non-syndromal craniosynostosis were
included (Table 1). All patients were hemodynamically stable
without vasoactive drugs and breathing spontaneously with
a FiO2 < 0.6. They received opioids or acetaminophen as pain relief
and were not sedated or receiving muscle relaxation. Patients did
not receive (par)enteral nutrition other than intravenous glucose as
per standard care (4e6 mg kg1 min1).173.2. Laboratory values and hormone concentrations
Patients were hyperglycemic during standard glucose infusion
(SG), while during LG plasma glucose levels were lower and nor-
moglycemic (Fig. 2, Table 1). LG did not cause hypoglycemia, the
lowest plasma glucose was 5.1 mmol L1 (91.8 mg dL1). Insulin
plasma concentrations did not differ signiﬁcantly (Table 1).3.3. Stable isotope kinetics
Steady state conditions were achieved during the last 40 min of
each study period (data not shown).
Fig. 2. Glucose metabolism during low and standard glucose infusion in eight post-
surgical infants. Panel A. Plasma glucose concentration, mmol L1, mean  SD,
yp ¼ 0.02, Panel B. Endogenous glucose production mg kg1 min1, mean  SD,
zp ¼ 0.05.
Table 2
Glucose kinetics in eight post-surgical infants during two different glucose
infusions.a
LGd SGe P value
Glucose Rab/Rdc mg kg1 min1 5.3  1.5 6.4  1.5 0.14
Endogenous Glucose Production
mg kg1 min1
2.6  1.5 1.1  1.4 0.05
Fractional gluconeogenesis % of Rab 43  2 29  7 <0.01
Absolute Gluconeogenesis
mg kg1 min1
2.3  0.6 1.8  0.4 0.08
Glycogenolysis mg kg1 min1 0.3  0.9 0.7  1.1 0.08
a All values are depicted as mean  SD.
b Ra; rate of appearance.
c Rd; rate of disappearance.
d LG; Low glucose.
e SG; Standard glucose.
Table 1
Demographic and nutritional data of 8 post-surgical children.a
Age (months) 9.8  1.9
Gender (male: female) 6:2
Weight (kg.) 9.5  1.1
Height (cm) 74.3  3.0
PELODb 10.1  7.6
PRISM IIIc 7.4  3.7
PIM2d 14.2  2.8
LGe SGf P value
Glucose infusion
(mg kg1 min1)
2.6  0.1 5.2  0.1 <0.0001
VO2 (mL min1) 69  24 67  17 0.79
VCO2 (mL min1) 59  11 55  14 0.29
Resting energy expenditure
(kcal kg1 d1)
49.8  17.6 49.7  14.9 0.98
Respiratory quotient 0.88  0.14 0.83  0.10 0.37
Caloric intake
(kcal kg1 day1)
12.7  0.2 25.3  0.5 <0.0001
Caloric intake (%)g 24  1 47  2 <0.0001
Glucose (mmol L1) 5.9  0.6 7.5  1.7 0.02
Triglycerides (mmol L1) 0.38  0.25 0.43  0.20 0.54
Free fatty acids (mmol L1) 0.72  0.20 0.63  0.12 0.34
C-reactive protein (mg dL1) 24  13 26  16 0.61
Cortisol (nmol L1) 649  160 681  205 0.77
Insulin (pmol L1) 64  48 90  51 0.16
a All values are mean  SD.
b PELOD ¼ Pediatric Logistic Organ Dysfunction (17).
c PRISM III ¼ Pediatric Risk of Mortality III (20).
d PIM2 ¼ Pediatric index of Mortality (18, 19).
e LG ¼ Low glucose.
f SG ¼ Standard glucose.
g Caloric intake as percentage of requirements according to the Schoﬁeld equa-
tion (59).
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The deuterium enrichment of body water was 0.59  0.02 and
0.58  0.03 MPE, at LG and SG respectively. Glucose Ra did not
differ between glucose protocols (Table 2). EGP increased during LG
(Fig. 2, Table 2). Absolute gluconeogenesis and glycogenolysis were
not signiﬁcantly different (p ¼ 0.08) and glycogenolysis was not
signiﬁcantly different from zero (Table 2).
3.3.2. Amino acid kinetics
Leucine Ra, oxidation and NOLD did not differ (Table 3).
Phenylalanine and tyrosine Ra did not differ. Phenylalanine
hydroxylationwas signiﬁcantly higher at the lower glucose infusion
rate (Table 3). However, NHPD (Table 3) and the phenylalanine
hydroxylation fraction of the total phenylalanine Rd did not differ
(12  3% vs. 11  3%; LG vs. SG, p ¼ 0.07).
3.3.3. Protein metabolism
Whole body protein metabolism corresponding with leucine
kinetics was as follows (Fig. 3). Protein synthesis (4.7  0.5 vs.
4.80.8gkg1d1) andbreakdown(5.90.6vs.5.80.6gkg1d1)
did not differ between LG and SG respectively. Protein balance was
negative and did not differ (1.2 0.8 vs.1.0 0.6 g kg1 d1, LG vs.
SG). Whole body protein metabolism corresponding with phenylal-
anine and tyrosine kinetics was as follows (Fig. 3). Protein synthesis
(5.3  0.6 vs. 5.2  0.5 g kg1 d1) and breakdown (5.6  0.5 vs.
5.4  0.4 g kg1 d1) did not differ between LG and SG respectively.
Protein balancewasnegative and showeda statistically signiﬁcant but
not clinical relevant difference (0.3  0.1 vs.0.2  0.1 g kg1 d1;
LG vs. SG, p ¼ 0.04).
4. Discussion
Tight glucose control improves morbidity and mortality in
critically ill children, although hypoglycemia is a frequent andserious side effect of insulin therapy.5 In this study we showed that
in post-surgical children, normoglycemia could be achieved by
a reduced glucose infusion, without occurrence of hypoglycemia,
although no conclusion can be drawn outside our study interven-
tion period. The reduced glucose infusion, half of what is consid-
ered standard practice for age,17 can be considered an alternative to
insulin therapy in the initial phase of glycemic management.
Additionally we observed that EGP was not fully suppressed,
despite high plasma glucose levels. Moreover, reducing the glucose
infusion induced an increase in EGP without a signiﬁcant increase
in either gluconeogenesis or glycogenolysis (both p ¼ 0.08).
Furthermore, reduced glucose did not notably affect the negative
whole body protein balance, measured with leucine and phenyl-
alanine kinetics.
Our study is the ﬁrst to show the feasibility of reduced glucose
infusion in post-surgical children to prevent or treat hypergly-
cemia. We found that during LG plasma glucose levels were lower
and normoglycemic, not due to an increased rate of disposal or
decreased glucose production, but solely through a reduced glucose
infusion rate. Due to the paucity of data in children it is difﬁcult to
deﬁne lower limits of glucose infusion. Current recommendations
are based largely upon data for children extracted from the relation
between glucose intake and 1) glucose uptake by the brain, 2)
glucose oxidation, 3) endogenous glucose production (EGP), and 4)
protein and amino acid catabolism.17 Although conditions are
different in post-surgical children, we used these considerations to
determine whether LGwas within safe limits in our population. We
acknowledge that we did not quantify cerebral glucose uptake.
Additionally, exact determination of glucose oxidation with [13C]
Table 3
Leucine, phenylalanine and tyrosine kinetics in eight post-surgical infants during
two different glucose infusions.a
LGb SGc P value
Leucine Rad 160  15 158  16 0.68
Leucine oxidation 33 (22e82) 29 (22e62) 0.38
NOLDe 122  14 124  20 0.76
Phenylalanine Ra 70  6 68  5 0.25
Tyrosine Ra 39  2 37  2 0.06
Phenylalanine hydroxylation 8.4  1.7 7.4  1.6 0.04
NHPDf 61  6 61  6 1.0
a All values are measured in mmol kg1 h1 and depicted in mean SD, except for
Leucine oxidation which is depicted in median (range).
b LG; Low glucose.
c SG; Standard glucose.
d Ra; rate of appearance.
e NOLD; non-oxidative leucine disposal.
f NHPD; non-hydroxylation phenylalanine disposal.
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with our [13C]Leucine tracer. Therefore, we cannot provide clear
insight in the impact of LG on cerebral glucose uptake and utili-
zation or oxidation. However, glucose oxidation calculated from
the oxygen consumption and carbon dioxide production did not
change. Of greater importance, hypoglycemia did not occur during
low glucose infusion. This suggests that the reduced glucose
intake did not negatively impact cerebral glucose uptake or
utilization.
EGP rates in our infants, receiving 2.5 mg kg1 min1, were
lower than those measured in healthy infants, fasted for 8e9 h
(7.1  0.3 mg kg1 min1).36 So, although an increased EGP was
observed during LG, their productionwas not at their full potential.
During both glucose infusions glycogenolysis was almost
completely blocked. Glycogenolysis was probably suppressed by
elevated insulin levels and suppressed glucagon levels during
glucose infusion,37 although the latter could not bemeasured in our
study due to blood draw limitations. Considering the exogenous
glucose our patients received it is not likely that glycogen stores
were already depleted. Therefore, it appears safe to conclude that
our infants were capable of sustaining normoglycemia, without
a direct risk of developing hypoglycemia. However, conclusions
cannot be drawn for a longer period beyond the study period of
reduced glucose infusion we presented.
Of interest, even during SG, despite supraphysiological glucose
and insulin levels, EGPwasnot fully suppressed.During both glucose
infusions, gluconeogenesis constituted almost all of the EGP and itFig. 3. Whole body protein metabolism during low and standard glucose infusion in eight po
B. protein breakdown, Panel C. protein balance; Values are g kg1 d1, mean  SD, yp ¼ 0.0appears that gluconeogenesis in contrast to glycogenolysis was
unresponsive to insulin, high glucose concentrations and/or infu-
sion. A clear association exists between increased contribution of
gluconeogenesis and insulin resistance.38 The expression of
phosphoenolpyruvate-carboxy-kinase (PEPCK), the rate-limiting
enzyme for gluconeogenesis, is increased and less sensitive to
insulin during critical illness.39 Therefore, we hypothesize that the
increase in EGP and moreover gluconeogenesis during LG does not
indicate that LG was below the threshold, but that it might indicate
a certain state of hepatic insulin resistance in these post-surgical
infants.
Our study was not able to show which precursors (amino acids,
glycerol or lactate) were predominantly used to fuel gluconeo-
genesis. Although our static measurements of lipid metabolism
(FFA and triglycerides) did not differ (Table 1), these results do not
exclude a change in lipolysis, because we didn’t conﬁrm this by
means of glycerol isotope tracer infusions. Another important
gluconeogenic precursor is lactate. However, as our patients were
hemodynamically stable with good organ perfusion, lactate levels
are not expected to have increased during either intervention.
Finally, protein or amino acid catabolism were not signiﬁcantly
increased.
Although LG did not affect leucine kinetics andmore speciﬁcally
oxidation, phenylalanine hydroxylation was slightly but statisti-
cally signiﬁcant higher during LG. Increased availability of plasma
amino acids, a known stimulant of hydroxylation,40e42 can be ruled
out as an explanation. Furthermore, a physiological response to
cope with an energy shortage is unlikely as the leucine oxidation
was unaffected. Possibly, phenylalanine catabolism was induced to
provide gluconeogenic precursors. Products derived from phenyl-
alanine hydroxylation can be used for gluconeogenesis, while
oxidized leucine can merely be used for the ketogenic pathway.43
This could explain the difference in catabolism between phenylal-
anine and leucine. These slight differences in amino acid or protein
metabolism during low glucose infusion are not likely to have
clinical relevance.
Whole body protein balance was as expected slightly negative
during both study periods and consistent with those obtained from
septic infants and children.33,34 In contrast with our data, normo-
glycemia, independent of plasma insulin levels, improved protein
turnover after abdominal surgery in adults.44 Our different results
may be explained by differences in patient populations and the
approach used. Furthermore, there are tissue and age speciﬁc
differences in the metabolic processes.45 However, consistent with
our data, it has been shown in neonates that different glucosest-surgical infants. Leu ¼ leucine, Phe ¼ Phenylalanine. Panel A. protein synthesis, Panel
4; LG vs. SG.
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a deﬁciency in energy supply is not solely responsible for protein
catabolism.47 Proteolysis during critical illness is usually caused by
activation of the ubiquitin-proteasome proteolytic pathway (UPP)
in muscle initiated by activation of caspase 3,48,49 and pathophys-
iological triggers include activation of lysosome-50 and calpain-
dependent pathways.51 Furthermore, there appears to be a link
between muscle wasting and insulin resistance.52e54
There are some limitations to our study, some of them inherent
to studying critically ill children. Our sample size was small and
conclusions from our study are restricted to post-surgical infants.
Substrate metabolism greatly differs between infants, children and
adolescents both for glucose and amino acid metabolism.17,45
Furthermore, various diagnoses, such as trauma, burns or sepsis,
as well as differences between single and multi-organ failure yield
a different response. We also acknowledge that the negative
glycogenolysis rates are physiological not possible. This might be
explained by a consistent underestimation of the EGP by the tracer
model, as part of the diluted tracer pool, due to newly produced
glucose, is taken up by the liver again.55 These limitations, however,
do not weaken the conclusions drawn from our study. Finally,
although our study does not provide data on reduced glucose
infusion for longer than 4 h this approach appears to be safe in the
initial postoperative phase which duration is individually depen-
dent but usually lasts 6-24 h. Conﬁrmatory studies with reduced
glucose infusion during this study period are warranted.5. Conclusion
Reduced glucose infusion, half of what is considered standard
practice for age, in the initial post-surgical phase reduced high
glucose levels in infants without occurrence of hypoglycemia.
Additionally we observed that the endogenous glucose production
was not fully suppressed and almost entirely relied on gluconeo-
genesis, despite high plasma glucose levels and exogenous glucose
infusion. Furthermore, protein and amino acid catabolism was not
exacerbated during the reduced glucose infusion. Although further
studies on the optimal time period and (long term) clinical impli-
cations are warranted, reduced glucose infusion can be considered
an alternative to insulin therapy in the initial glycemic post-
operative management.
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